AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00313781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.
Study NCT00313781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Prednisone is administered at a dose of 5 mg twice daily.
Study NCT02767297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169
Study NCT04887376 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mirror frame
Description: Combined Mirror and NMES therapy
Study NCT04887376 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Only NMES therapy
Study NCT00305929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with Tookad VTP
Study NCT00305929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with Tookad VTP
Description: Tookad 2 mg/kg
Study NCT00305929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with Tookad VTP
Description: 2 mg/kg
Study NCT01416597 — intervention group
Intervention type: BIOLOGICAL
Intervention: Vaccines
Description: Unadjuvanted, monovalent, and trivalent vaccines, and vaccines delivered intramuscularly, intradermally, or intranasally, depending on what is found in the included studies.
Study NCT01261780 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MC-5A
Description: 45 minutes daily x 10 treatments (given over the course of 2 weeks)
Study NCT01261780 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: Sham therapy daily x 45 minutes for 10 treatments (given over course of 2 weeks)
Study NCT03977740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chest PNF
Description: Chest PNF technique includes oblique downward pressure at sternum, diagonal pressure at lower rib cage at supine line, caudal medial pressure at side lying, Caudal pressure at ribcage at prone lying, dorsal and caudal pressure at prone on elbow.
Study NCT03977740 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: conventional chest physiotherapy treatment, which includes Deep breathing exercise, Diaphragmatic breathing exercise, segmental breathing exercise and purse lip breathing and incentive spirometer
Study NCT03021161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Formula
Description: The intervention group will receive once daily capsules containing 109 CFU of Lactobacillus rhamnosus HN001, Lactobacillus paracasei Lpc-37 and Bifidobacterium animalis ssp. Lactis HN019
Study NCT03021161 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Capsule containing no probiotic
Study NCT03980353 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: The questionnaires have two parts: a general part and a second part focused on the integration in community of the type 1 diabetes children with specific questions about blood glucose, mealtimes, sporting activities and school trips.
Study NCT04284462 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Flavored carbonated soft drink (CSD)
Description: 1-2 cans/day (330 ml per can)
Study NCT04284462 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavored carbonated soft drink (CSD)
Description: 1-2 cans/day (330 ml per can)
Study NCT02061527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reconstruction with ADM.
Description: If the patient wishes to undergo immediate implant based reconstruction, and meets the selection criteria for entering the study, she is randomly selected to be treated according to Group A or Group B. Group A (no intervention) will be reconstructed with expander or anatomical gel implant without ADM, using complete muscle coverage. Group B (Intervention) will be reconstructed with expander or anatomical gel implant using partial muscle coverage in conjunction with ADM.
Study NCT02061527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin or nipple sparing mastectomy
Description: Mastectomy for invasive or pre-invasive breast cancer
Study NCT02061527 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin or nipple sparing mastectomy
Description: Mastectomy for invasive or pre-invasive breast cancer
Study NCT02061527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reconstruction with implant
Description: Immediate breast reconstruction with implant
Study NCT02061527 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reconstruction with implant
Description: Immediate breast reconstruction with implant
Study NCT02061527 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total submuscular coverage
Description: Implant based breast reconstruction with total submuscular coverage
Study NCT02061527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial submuscular coverage
Description: Implant based breast reconstruction with partial submuscular coverage
Study NCT03497598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannose
Description: The powder is dispensed in 2g neutral sticks and ready to be dissolved in 100ml of water for daily oral ingestion.
Study NCT03497598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose
Description: The powder is dispensed in 2g neutral sticks and ready to be dissolved in 100ml of water for daily oral ingestion.
Study NCT01116856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Different groups will carry out different exercise protocols during 16 weeks under the same nutritional intervention.
Study NCT04303728 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Muscle ultrasound
Description: The muscle thickness and muscle quality will be assessed on ultrasound
Study NCT04184388 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolysed Red Ginseng Extract
Description: once a day for 1 p.o., after breakfast(10 ml/day, Hydrolysed Red Ginseng extract for 1g/day) for 12 week
Study NCT04184388 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once a day for 1 p.o., after breakfast(10 ml/day, Hydrolysed Red Ginseng extract for 0g/day) for 12 week
Study NCT00307008 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax 23™
Description: Single dose intramuscular injection
Study NCT01381562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: GSK2251052
Description: Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
Study NCT01381562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Reconstituted, added to 100mL 0.9% NaCl solution and administered via IV infusion
Study NCT01381562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: saline placebo
Study NCT01381562 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: saline placebo
Study NCT00798278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urokinase
Description: Chest tube with intrapleural urokinase infusion for 3 days
Study NCT00798278 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Video-Assisted Thoracoscopic
Description: Video-Assisted Thoracoscopic decortication
Study NCT01630278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Very premature infants with a large ductus, selected by an early echocardiogram, will receive ibuprofen before 12 hours of life
Study NCT01630278 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Very premature infants with a large ductus, selected by an early echocardiogram, will receive placebo before 12 hours of life
Study NCT02572284 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: The first group of patients to enter the study will receive 5 Gy of SBRT per day for 5 days, the second group will receive 6 Gy per day for 5 days. Each treatment will take about 3 minutes and be given as an outpatient at Moffitt Cancer Center.
Study NCT02572284 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatectomy
Description: About 4-6 weeks after SBRT, participants will have a prostatectomy.
Study NCT02572284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Questionnaires
Description: Patient assessed health-related quality of life (HRQOL). Quality of Life (QOL) will be assessed using Prostate Symptom Score (IPSS), rectal assessment scale (RAS), sexual health inventory for men (SHIM), and Expanded Prostate Cancer Index Composite (EPIC) patient questionnaires: administered prior to SBRT, and at 2 weeks, 4 weeks, 2 months and then every 3 months up to 18 months post-prostatectomy.
Study NCT01361841 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Latanoprost, bimatoprost, travoprost
Description: topic drops, once a day at bedtime, for years
Study NCT01361841 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: travoprost, latanoprost and bimatoprost
Description: one drop once a day for life
Study NCT00968422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-384
Description: 3 escalating doses will be administered daily for 21 days
Study NCT00968422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo to ABT-384
Description: Doses will be administered daily for 21 days
Study NCT00836550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: The participants saw a 6 minute video
Study NCT00836550 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: in-person HIV pre-test counseling
Study NCT03599180 — intervention group
Intervention type: DEVICE
Intervention: microdialysis
Description: Use microdialysis skill to collect dialyzate at sensitization acupoints
Study NCT04355988 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nonsurgical root canal therapy
Description: After administration of LA and rubber dam isolation, acess cavity will be prepared using carbide burs in high speed hand piece with copious irrigation. Working length will be determined using root ZX apex locator and will be verified radiographically. Canal preparation will be done with protaper rotary instruments in which Sx to S2 will be used to shape the canals and F1 and F2 will be used to finish until the apex. 5ml of 5.25% NaOCl will be used as irrigant after each instrument. After instrumentation , the canals will be irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals will be dried with absorbent paper points, filled with calcium hydroxide paste and access cavity will be restored with IRM. Patients will be recalled after 1 week.At the next appointment, after paste removal, copious irrigation with 5.25% NaOCl will be done and canals will be dried with paper points. Canals will be obturated with Gutta-Percha and ZOE based sealer.
Study NCT00826735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided imagery
Description: A relaxation focused guided imagery intervention was used through the remainder of pregnancy plus a physiologic guided imagery intervention was used during the third stage of labor.
Study NCT03062254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: radium-223 dichloride
Description: 6 doses of Radium-223
Study NCT03027791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participation in Virtual Reality experiences focused on a) education about the effects of high sodium foods on coronary arteries, blood pressure, the kidneys, and the cerebral vasculature, and b) stress management.
Study NCT03027791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Sessions
Description: 12 weekly group sessions that will provide education on topics related to hypertension, dietary sodium, physical activity and stress.
Study NCT03763565 — intervention group
Intervention type: BIOLOGICAL
Intervention: Bivalent or Quadrivalent HPV vaccines
Description: Vaccination with at least one dose of Bivalent or Quadrivalent HPV vaccines at least 5 years ago at the ages of 20-45 years
Study NCT03763565 — intervention group
Intervention type: OTHER
Intervention: Control group
Description: Thai women who did not receive HPV vaccination, either by bivalent or quadrivalent HPV vaccine but have received Pap smear at their ages 20-45 years at least 5 years ago from the current enrollment time
Study NCT03349398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uncut Roux-en-Y reconstruction
Description: Uncut Roux-en-Y Reconstruction All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
Study NCT03349398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y reconstruction
Description: Roux-en-Y Reconstruction All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Roux-en-Y construction will be used in this group.
Study NCT00933218 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: polyphenols (non-alcoholic beer)
Description: 1.0 - 1.5 l non-alcoholic beer per day; 3 weeks before and during a marathon run
Study NCT00933218 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: beverage without polyphenols
Description: 1.0 - 1.5 l of beverage without polyphenols (otherwise the same composition as non-alcoholic beer) per day; 3 weeks before and during a marathon run
Study NCT00978822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevidipine butyrate injectable emulsion
Description: Clevidipine butyrate injectable emulsion infusion starting at 2 mg/hour and titrating up for effect till 32 mg/h for up to 24 hours starting in the emergency department and continued in the critical care units.
Study NCT04495647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-Body Electromyostimulation
Description: Whole-Body Electromyostimulation (WB-EMS): Simultaneous, individually adjustable stimulation of 12 muscle groups using an interval approach with a duty cycle of 6s impulse/4s rest, bipolar electric current (impulse -frequency 85Hz, -width 350μs, rectangular pattern) will be applied.~After a 4-week conditioning period, 1.5x 20 min/week WB-EMS will be conducted for 4 weeks (total training duration 8 weeks). Easy to perform functional exercises focusing on balance, transfer ability, stepping and lower extremity strength/power will be done during WB-EMS. Exercise intensity will be individually prescribed and adjusted by rate of perceived exertion (RPE-Borg CR10 scale 4 (moderate) to 7 (hard)).~WB-EMS will be fully supervised one on one.~All three arms will receive the same intervention.
Study NCT02266108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ESTIMA Intervention
Description: This study involves the evaluation of ESTIMA, a microfinance and gender equity intervention among women working as sex workers in Tijuana, Mexico.
Study NCT02266108 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ESTIMA Intervention
Description: This study involves the evaluation of ESTIMA, a microfinance and gender equity intervention among women working as sex workers in Tijuana, Mexico.
Study NCT04225325 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: SYMTUZA
Description: DESCOVY+REZOLSTA
Study NCT04495647 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole-Body Electromyostimulation
Description: Whole-Body Electromyostimulation (WB-EMS): Simultaneous, individually adjustable stimulation of 12 muscle groups using an interval approach with a duty cycle of 6s impulse/4s rest, bipolar electric current (impulse -frequency 85Hz, -width 350μs, rectangular pattern) will be applied.~After a 4-week conditioning period, 1.5x 20 min/week WB-EMS will be conducted for 4 weeks (total training duration 8 weeks). Easy to perform functional exercises focusing on balance, transfer ability, stepping and lower extremity strength/power will be done during WB-EMS. Exercise intensity will be individually prescribed and adjusted by rate of perceived exertion (RPE-Borg CR10 scale 4 (moderate) to 7 (hard)).~WB-EMS will be fully supervised one on one.~All three arms will receive the same intervention.
Study NCT04225325 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: DESCOVY+DOLUTEGRAVIR
Description: DESCOVY+DOLUTEGRAVIR
Study NCT04225325 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SYMTUZA+DOLUTEGRAVIR
Description: DESCOVY+REZOLSTA+DTG
Study NCT02840331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: St. John's Wort
Description: Single oral doses (900 milligram) 2-4 hours before laparoscopy
Study NCT02840331 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photodynamic diagnostic and therapy
Description: Intraoperative irradiation with light (photodynamic diagnosis (PDD) and therapy (PDT), with the appropriate wavelength (390-440 nanometer) over 15 minutes
Study NCT01884792 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sitting OGTT
Study NCT01884792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sitting OGTT
Study NCT01884792 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standing OGTT
Study NCT01884792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standing OGTT
Study NCT01884792 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sitting CGM
Study NCT01884792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sitting CGM
Study NCT01884792 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standing CGM
Study NCT01884792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standing CGM
Study NCT00686816 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low calorie diet
Description: low calorie diet
Study NCT00686816 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olestra
Description: low calorie Olestra diet
Study NCT00428402 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus Group Discussion
Description: Focus groups meeting for up to 1 hour during the regular school day.
Study NCT01147614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Therapy (BCBT)
Description: BCBT: 8-12 sessions over 16 weeks of cognitive-behavioral therapy administered by Master's-level clinicians in primary care setting
Study NCT01147614 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Specialty mental health care referral (SMHC)
Description: SMHC: specialty mental health care referrals provided
Study NCT00576979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00576979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT02791880 — intervention group
Intervention type: PROCEDURE
Intervention: Transcatheter Aortic Valve Replacement
Description: The investigators will collect blood and urine samples from patients with aortic stenosis who are undergoing transcatheter aortic valve replacement.
Study NCT04997122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olive pomace oil
Description: Volunteers consumed during 4 weeks 45 g/d of olive pomace oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
Study NCT04997122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High oleic acid sunflower oil
Description: Volunteers consumed during 4 weeks 45 g/d of oleic acid-rich sunflower oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.
Study NCT01735409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX + DDP
Description: ABX 260 mg/m2 day 1 + DDP 75mg/m2 day 1
Study NCT01735409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX + DDP
Description: ABX 140 mg/m2 day 1,8 + DDP 75mg/m2 day 1
Study NCT01735409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX + DDP
Description: ABX 100 mg/m2 day 1,8,15 + DDP 75mg/m2 day 1
Study NCT03586726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan
Description: In Period 1, balovaptan was administered alone as a once daily (qd) dose on Days 1 to 10.~In Period 2, balovaptan was administered as a qd dose on Days 7 to 16.
Study NCT03586726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: In Period 2, 600 mg of rifampicin will be administered alone as a qd dose from Day 1 to Day 6, and as a qd dose on Days 7 to 16.
Study NCT01121276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: 0.2 U/kg body weight injected subcutaneously (under the skin)
Study NCT01121276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: 0.2 U/kg body weight injected subcutaneously (under the skin)
Study NCT02147925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide combined with metformin
Description: Liraglutide, 0.6mg per day for the first week, and will be increased to 1.2mg per day for the second week, and finally 1.8mg per day since the third week
Study NCT02147925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine combined with metformin
Description: The initial dose will be 0.2 unit/kg/d